Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
36
CVAC Quote, Financials, Valuation and Earnings
Last price:
$3.01
Seasonality move
:
-28.45%
Day range:
$2.93 - $3.02
52-week range:
$2.22 - $5.28
Dividend yield:
0%
P/E ratio:
5.45x
P/S ratio:
1.13x
P/B ratio:
0.83x
Volume:
176.5K
Avg. volume:
590.7K
1-year change:
-26.35%
Market cap:
$670.8M
Revenue:
$58.2M
EPS (TTM):
$0.55
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CVAC
CureVac NV
|
$150.6M | $1.54 | -66% | -69.73% | $7.38 |
|
AFMD
Affimed NV
|
$1.5M | -$1.06 | -50.03% | -42.4% | $18.90 |
|
BAYRY
Bayer AG
|
$11B | $0.17 | -5.74% | -27.67% | -- |
|
BNTX
BioNTech SE
|
$561.1M | -$1.75 | -24.68% | -74.38% | $137.54 |
|
IFRX
InflaRx NV
|
$84.1K | -$0.27 | 5602.11% | -2.23% | $8.04 |
|
IMTX
Immatics NV
|
$17.4M | -$0.28 | -5.77% | -3.64% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CVAC
CureVac NV
|
$2.99 | $7.38 | $670.8M | 5.45x | $0.00 | 0% | 1.13x |
|
AFMD
Affimed NV
|
$1.24 | $18.90 | $20.3M | -- | $0.00 | 0% | 20.08x |
|
BAYRY
Bayer AG
|
$4.87 | -- | $19.1B | -- | $0.03 | 0.6% | 0.38x |
|
BNTX
BioNTech SE
|
$114.13 | $137.54 | $27.4B | 184.86x | $0.00 | 0% | 8.34x |
|
IFRX
InflaRx NV
|
$2.51 | $8.04 | $147.8M | -- | $0.00 | 0% | 800.79x |
|
IMTX
Immatics NV
|
$7.10 | -- | $863M | -- | $0.00 | 0% | 5.70x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CVAC
CureVac NV
|
-- | 2.309 | -- | 6.10x |
|
AFMD
Affimed NV
|
31.93% | 0.815 | 16.35% | 1.76x |
|
BAYRY
Bayer AG
|
-- | 0.334 | -- | 0.81x |
|
BNTX
BioNTech SE
|
1.26% | 0.543 | 0.96% | 7.10x |
|
IFRX
InflaRx NV
|
-- | 4.286 | -- | 4.34x |
|
IMTX
Immatics NV
|
-- | 1.740 | -- | 3.87x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CVAC
CureVac NV
|
$519.1M | $404.1M | 21.3% | 21.3% | 75.06% | $381.2M |
|
AFMD
Affimed NV
|
-- | -$15.7M | -127.62% | -158.94% | -9594.22% | -$13.2M |
|
BAYRY
Bayer AG
|
$5.4B | -$4.2B | -2.23% | -2.79% | -37.17% | $1.6B |
|
BNTX
BioNTech SE
|
$1.2B | $11.5M | -2.32% | -2.35% | 13.39% | -$770.2M |
|
IFRX
InflaRx NV
|
$216K | -$16.9M | -61.55% | -61.55% | -14084.63% | -$11.2M |
|
IMTX
Immatics NV
|
-- | $565.3K | -16.88% | -16.88% | -4.19% | -$42M |
CureVac NV vs. Competitors
-
Which has Higher Returns CVAC or AFMD?
Affimed NV has a net margin of 68.44% compared to CureVac NV's net margin of -9767.12%. CureVac NV's return on equity of 21.3% beat Affimed NV's return on equity of -158.94%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV95.56% $1.65 $809.4M AFMDAffimed NV-- -$1.03 $28.2M -
What do Analysts Say About CVAC or AFMD?
CureVac NV has a consensus price target of $7.38, signalling upside risk potential of 144.29%. On the other hand Affimed NV has an analysts' consensus of $18.90 which suggests that it could grow by 1421.72%. Given that Affimed NV has higher upside potential than CureVac NV, analysts believe Affimed NV is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV3 4 0 AFMDAffimed NV5 1 0 -
Is CVAC or AFMD More Risky?
CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Affimed NV has a beta of 2.063, suggesting its more volatile than the S&P 500 by 106.315%.
-
Which is a Better Dividend Stock CVAC or AFMD?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Affimed NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. Affimed NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or AFMD?
CureVac NV quarterly revenues are $543.2M, which are larger than Affimed NV quarterly revenues of $170.5K. CureVac NV's net income of $371.8M is higher than Affimed NV's net income of -$16.7M. Notably, CureVac NV's price-to-earnings ratio is 5.45x while Affimed NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.13x versus 20.08x for Affimed NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV1.13x 5.45x $543.2M $371.8M AFMDAffimed NV20.08x -- $170.5K -$16.7M
-
Which has Higher Returns CVAC or BAYRY?
Bayer AG has a net margin of 68.44% compared to CureVac NV's net margin of -41.96%. CureVac NV's return on equity of 21.3% beat Bayer AG's return on equity of -2.79%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV95.56% $1.65 $809.4M BAYRYBayer AG48.94% -$1.17 $34.3B -
What do Analysts Say About CVAC or BAYRY?
CureVac NV has a consensus price target of $7.38, signalling upside risk potential of 144.29%. On the other hand Bayer AG has an analysts' consensus of -- which suggests that it could grow by 55.85%. Given that CureVac NV has higher upside potential than Bayer AG, analysts believe CureVac NV is more attractive than Bayer AG.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV3 4 0 BAYRYBayer AG0 0 0 -
Is CVAC or BAYRY More Risky?
CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bayer AG has a beta of 1.041, suggesting its more volatile than the S&P 500 by 4.07%.
-
Which is a Better Dividend Stock CVAC or BAYRY?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bayer AG offers a yield of 0.6% to investors and pays a quarterly dividend of $0.03 per share. CureVac NV pays -- of its earnings as a dividend. Bayer AG pays out -80.89% of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or BAYRY?
CureVac NV quarterly revenues are $543.2M, which are smaller than Bayer AG quarterly revenues of $11B. CureVac NV's net income of $371.8M is higher than Bayer AG's net income of -$4.6B. Notably, CureVac NV's price-to-earnings ratio is 5.45x while Bayer AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.13x versus 0.38x for Bayer AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV1.13x 5.45x $543.2M $371.8M BAYRYBayer AG0.38x -- $11B -$4.6B
-
Which has Higher Returns CVAC or BNTX?
BioNTech SE has a net margin of 68.44% compared to CureVac NV's net margin of 15.91%. CureVac NV's return on equity of 21.3% beat BioNTech SE's return on equity of -2.35%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV95.56% $1.65 $809.4M BNTXBioNTech SE85.63% $0.89 $21.6B -
What do Analysts Say About CVAC or BNTX?
CureVac NV has a consensus price target of $7.38, signalling upside risk potential of 144.29%. On the other hand BioNTech SE has an analysts' consensus of $137.54 which suggests that it could grow by 20.51%. Given that CureVac NV has higher upside potential than BioNTech SE, analysts believe CureVac NV is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV3 4 0 BNTXBioNTech SE11 5 0 -
Is CVAC or BNTX More Risky?
CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioNTech SE has a beta of 0.217, suggesting its less volatile than the S&P 500 by 78.349%.
-
Which is a Better Dividend Stock CVAC or BNTX?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or BNTX?
CureVac NV quarterly revenues are $543.2M, which are smaller than BioNTech SE quarterly revenues of $1.4B. CureVac NV's net income of $371.8M is higher than BioNTech SE's net income of $217.9M. Notably, CureVac NV's price-to-earnings ratio is 5.45x while BioNTech SE's PE ratio is 184.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.13x versus 8.34x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV1.13x 5.45x $543.2M $371.8M BNTXBioNTech SE8.34x 184.86x $1.4B $217.9M
-
Which has Higher Returns CVAC or IFRX?
InflaRx NV has a net margin of 68.44% compared to CureVac NV's net margin of -14092.9%. CureVac NV's return on equity of 21.3% beat InflaRx NV's return on equity of -61.55%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV95.56% $1.65 $809.4M IFRXInflaRx NV-5376.61% -$0.33 $72.9M -
What do Analysts Say About CVAC or IFRX?
CureVac NV has a consensus price target of $7.38, signalling upside risk potential of 144.29%. On the other hand InflaRx NV has an analysts' consensus of $8.04 which suggests that it could grow by 220.48%. Given that InflaRx NV has higher upside potential than CureVac NV, analysts believe InflaRx NV is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV3 4 0 IFRXInflaRx NV3 1 0 -
Is CVAC or IFRX More Risky?
CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.675, suggesting its more volatile than the S&P 500 by 67.534%.
-
Which is a Better Dividend Stock CVAC or IFRX?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or IFRX?
CureVac NV quarterly revenues are $543.2M, which are larger than InflaRx NV quarterly revenues of $136.2K. CureVac NV's net income of $371.8M is higher than InflaRx NV's net income of -$19.2M. Notably, CureVac NV's price-to-earnings ratio is 5.45x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.13x versus 800.79x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV1.13x 5.45x $543.2M $371.8M IFRXInflaRx NV800.79x -- $136.2K -$19.2M
-
Which has Higher Returns CVAC or IMTX?
Immatics NV has a net margin of 68.44% compared to CureVac NV's net margin of -16.95%. CureVac NV's return on equity of 21.3% beat Immatics NV's return on equity of -16.88%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV95.56% $1.65 $809.4M IMTXImmatics NV-- -$0.12 $427.2M -
What do Analysts Say About CVAC or IMTX?
CureVac NV has a consensus price target of $7.38, signalling upside risk potential of 144.29%. On the other hand Immatics NV has an analysts' consensus of -- which suggests that it could grow by 135.92%. Given that CureVac NV has higher upside potential than Immatics NV, analysts believe CureVac NV is more attractive than Immatics NV.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV3 4 0 IMTXImmatics NV6 0 0 -
Is CVAC or IMTX More Risky?
CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immatics NV has a beta of 0.743, suggesting its less volatile than the S&P 500 by 25.688%.
-
Which is a Better Dividend Stock CVAC or IMTX?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or IMTX?
CureVac NV quarterly revenues are $543.2M, which are larger than Immatics NV quarterly revenues of $55.6M. CureVac NV's net income of $371.8M is higher than Immatics NV's net income of -$9.4M. Notably, CureVac NV's price-to-earnings ratio is 5.45x while Immatics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.13x versus 5.70x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV1.13x 5.45x $543.2M $371.8M IMTXImmatics NV5.70x -- $55.6M -$9.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 26
Power Solutions International [PSIX] is down 5.45% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.71% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 1.75% over the past day.
